CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE SUCCINATE
✉ Email this page to a colleague
All Clinical Trials for DESVENLAFAXINE SUCCINATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00256685 ↗ | Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2004-09-01 | The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators. |
| NCT00283842 ↗ | Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-03-01 | The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. |
| NCT00369343 ↗ | Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-09-01 | Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of major depressive disorder (MDD), for vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri- and postmenopausal. |
| NCT00369434 ↗ | Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2006-06-01 | The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women. |
| NCT00384033 ↗ | Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder | Completed | Pfizer | Phase 3 | 2006-09-01 | The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder. |
| NCT00397176 ↗ | Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2006-11-01 | Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DESVENLAFAXINE SUCCINATE
Condition Name
Clinical Trial Locations for DESVENLAFAXINE SUCCINATE
Trials by Country
Clinical Trial Progress for DESVENLAFAXINE SUCCINATE
Clinical Trial Phase
Clinical Trial Sponsors for DESVENLAFAXINE SUCCINATE
Sponsor Name
